To read the full story, subscribe or sign in.

Vitae Pharmaceuticals patents Menin/MLL interaction inhibitors

Jan. 2, 2018

BioWorld Science Cancer Patents

Today's news in brief

BioWorld

BioWorld briefs for May 11, 2026.

Rendering of a key measles protein targeted by neutralizing human antibodies

First measles treatment advances as vaccination rates drop

BioWorld

Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...

Infensa Bioscience identifies new ASIC blockers

BioWorld Science

Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.

Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst

BioWorld

Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...

Circulating sncRNA transcriptome in diabetic kidney disease and SGLT2 inhibitor treatment

BioWorld Science

Small noncoding RNAs (sncRNAs), including miRNAs, piRNAs and snoRNAs, can provide further biological insights into the mechanisms of chronic kidney disease (CKD)...